Knight Therapeutics | GUD - Selling And Administration Expenses

Stock Price
8.34
Daily Change
-0.30 -3.47%
Monthly
8.74%
Yearly
43.79%
Q2 Forecast
8.51

Knight Therapeutics reported CAD35.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Avita Medical AUD 19.03M 1.95M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Cronos Group USD 17.35M 2.1M Mar/2026
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Moderna USD 173M 135M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Organigram Holdings CAD 7.73M 1.13M Dec/2025
Organon & Co USD 433M 34M Dec/2025
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025